Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART,
a clinical stage biotechnology company developing regenerated organs for
transplant, initially focused on the trachea, reports unaudited
financial results for the three and nine months ended September 30, 2014.
- Operating income of $24.9 million for the quarter, up 32% versus last year - Operating margin of 11.4%, compared to 9.0% last year - GAAP earnings of $0.24 per share for the quarter, compared to $0.26 per share last year
- Adjusted EPS of $0.24 for the quarter, up 33% compared to $0.18 last year - Orders up 14% and backlog of $353 million up 23%, compared to last year - Increased outlook for the year to a range of $0.87 to $0.91 per share OAK BROOK, Ill.
PHILADELPHIA, PA --
NEW ORLEANS, LA --
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.